

Contents

Abbreviations	vii
WHO Expert Committee on Specifications for Pharmaceutical Preparations	ix
Introduction	1
1. General policy	4
1.1 Process for the development of WHO norms and standards	4
1.2 Participation in meetings of the Expert Committee on Specifications for Pharmaceutical Preparations	5
1.3 Open session	6
1.3.1 Introduction and welcome	6
2. General updates and matters for information	8
2.1 Cross-cutting pharmaceutical quality assurance issues	8
2.1.1 Local manufacturing	8
2.1.2 Member State mechanism	9
2.1.3 Expert Committee on Biological Standardization	9
2.1.4 Expert Committee - selection and use of the <i>WHO Model List of Essential Medicines</i>	10
2.1.5 Antimicrobial resistance	11
2.1.6 International Conference of Drug Regulatory Authorities	12
2.2 International collaboration	12
2.2.1 International Atomic Energy Agency	12
2.2.2 Pharmacopoeial Discussion Group	13
2.2.3 United Nations Children's Fund	13
3. Quality assurance - collaboration initiatives	15
3.1 International meetings of world pharmacopoeias	15
3.2 Inspection guidelines and good practices	15
3.2.1 Revision of <i>WHO good manufacturing practices for sterile pharmaceutical products</i>	15
3.2.2 <i>Good manufacturing practices for biotherapeutic products</i>	16
4. Nomenclature, terminology and databases	18
4.1 International Nonproprietary Names for pharmaceutical substances	18
4.2 Quality assurance terminology	18
4.3 Guidelines and guidance texts adopted by the Expert Committee	18
5. Prequalification of priority essential medicines and active pharmaceutical ingredients	20
5.1 Update on the prequalification of medicines	20
5.2 Update on the prequalification of active pharmaceutical ingredients	20
6. Quality control - prequalification and WHO monitoring projects	22
6.1 Update on the prequalification of quality control laboratories	22
6.2 Update on WHO quality monitoring projects	22



7. Quality control - national laboratories	23
7.1 External Quality Assurance Assessment Scheme	23
8. Quality control - specifications and tests: <i>The International Pharmacopoeia</i>	24
8.1 Update	24
8.2 Workplan 2018-2019	24
8.3 Procedure for the development, revision and omission of monographs and other texts for <i>The International Pharmacopoeia</i>	26
8.4 General policy - transition from microbiological to physicochemical assays in monographs on capreomycin active pharmaceutical ingredient and products	27
8.5 General chapters	27
8.5.1 Limit test for heavy metals	27
8.5.2 Polymorphism	28
8.5.3 Dissolution test for solid oral dosage forms	29
8.5.4 General notice: solubility	29
8.6 Specifications and draft monographs for medicines, including paediatric and radiopharmaceutical medicines	29
8.6.1 Medicines for maternal, newborn, child and adolescent health	29
8.6.2 Antimalarial medicines	31
8.6.3 Antituberculosis medicines	31
8.6.4 Antiviral medicines including antiretrovirals	32
8.6.5 Medicines for tropical diseases	33
8.6.6 Ophthalmological and dermatological medicines	34
9. Quality control - international reference materials	35
9.1 Update on International Chemical Reference Substances, including the report of the custodial centre of the dedicated ECSPP subgroup on the International Chemical Reference Substances	35
10. General policy - chemistry	36
10.1 Revision of guidance on representation of graphic formulae	36
11. Quality assurance - good manufacturing practices and inspection	37
11.1 Interpretation of <i>Guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems</i>	37
11.2 Good manufacturing practices for validation	38
11.2.1 General main text	38
11.2.2 Analytical procedure validation	39
11.2.3 Validation of computerized systems	40
11.2.4 Qualification	40
11.3 Update on review of existing WHO inspection guidance, including <i>Guidelines for inspection of drug distribution channels and Quality system requirements for national good manufacturing practice inspectorates</i>	41
11.3.1 Guidelines for inspection of drug distribution channels	42
11.3.2 Quality system requirements for national good manufacturing practice inspectorates	42
11.4 Update and recommendations from inspectors' meeting, including on good manufacturing practices and environmental issues	42

11.5	Inquiry regarding production of "water for injection"	43
11.6	Proposal for good chromatography practices	44
12.	Quality assurance - distribution and supply chain	45
12.1	Guidelines on import procedures for medical products	45
12.2	Update on review of existing WHO guidance, procedures and operational documents for pharmaceutical procurement	45
12.2.1	New guidance on shelf-life for supply and procurement of medicines	45
12.2.2	Update of listing of stability conditions for WHO Member States	46
13.	Regulatory guidance and model schemes	47
13.1	Proposal to waive in vivo bioequivalence requirements for medicines included in the <i>WHO Model List of Essential Medicines</i>	47
13.1.1	Experimental pathway	48
13.1.2	Regulatory pathway	49
13.1.3	Prioritization exercise	49
13.2	WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce	50
13.3	Good practice guidance document on implementing the collaborative procedures	51
13.4	Guidance document to support and facilitate the implementation of quality management systems for national regulatory authorities	52
13.5	Good regulatory practices	52
14.	Miscellaneous	53
14.1	Update of WHO/UNFPA prequalification guidance for contraceptive devices and condoms	53
15.	Closing remarks	54
16.	Summary and recommendations	55
	Acknowledgements	60
	References	83
	Annex 1	
	Procedure for the development of World Health Organization medicines quality assurance guidelines	87
	Annex 2	
	Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products	
	Part 2: Interpretation of <i>Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products</i>	93
	Annex 3	
	Good manufacturing practices: guidelines on validation	119
	Appendix 1 Validation of heating, ventilation and air-conditioning systems	135
	Appendix 2 Validation of water systems for pharmaceutical use	136
	Appendix 3 Cleaning validation	137
	Appendix 4 Analytical procedure validation	148

Appendix 5 Validation of computerized systems	160
Appendix 6 Guidelines on qualification	181
Appendix 7 Non sterile process validation	190
Annex 4	
Protocol to conduct equilibrium solubility experiments for the purpose of Biopharmaceutics Classification System-based classification of active pharmaceutical ingredients for biowaiver	203
Annex 5	
Guidelines on import procedures for medical products	219
Annex 6	
Good practices of national regulatory authorities in implementing the collaborative registration procedures for medical products	233
Appendix 1 An example of information to applicants for registration via the WHO collaborative registration procedure	257
Appendix 2 Verification for product submitted under the WHO collaborative procedure	259
Appendix 3 Abridged/abbreviated review for product submitted under the WHO collaborative procedure	263
Appendix 4 Additional information to be included in the screening checklist	279
Appendix 5 Example of a national regulatory authority reliance model approach: information, documentary evidence and assessment activity	281
Appendix 6 Model acknowledgement or approval letter for variations of products registered through the WHO collaborative procedure	283